<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56896">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01750333</url>
  </required_header>
  <id_info>
    <org_study_id>OBETAD-01</org_study_id>
    <nct_id>NCT01750333</nct_id>
  </id_info>
  <brief_title>Study on Correlation Between Vascular ET-1 and Adiponectin in Pediatric Obesity</brief_title>
  <official_title>Observational Retrospective Study on Correlation Between ET-1 and Ad in Obese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monica Montagnani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montagnani, Monica, M.D., Ph.D.</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to explore whether and how high circulating levels of endothelin-1
      (ET-1) in obese and overweight children may contribute to impair adiponectin (Ad)
      production, release and vascular activity
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Correlation between serum levels of ET-1 and Ad in lean, overweight and obese children</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>OBESITY</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Lean children</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight Children (OW)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese children (Ob)</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  serum

        -  plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        CHILDREN ATTENDING THE OUTPATIENT UNIT OF THE UNIVERSITY PEDIATRIC CLINIC
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children will be enrolled into lean, overweight or obese groups based on Body mass
             index (BMI) calculated according to standard methods.  International standards for
             sex-and age-specific BMI centiles for subjects aged 2-18 years will be used. The 95th
             centile of BMI reference is the cut off point for childhood obesity. Overweight and
             obese children are defined as those with a BMI higher than the centile curves.

        Exclusion Criteria:

          -  presence of renal, liver and/or cardiovascular diseases;

          -  hypertension;

          -  metabolic and/or endocrine disorders;

          -  genetic syndromes;

          -  histories of chronic allergies, acute infectious or inflammatory diseases during the
             last 3 months preceding the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Montagnani, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bari Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Bari Medical School - Dept Biomedical Sciences and Human Oncology</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 12, 2012</lastchanged_date>
  <firstreceived_date>December 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Montagnani, Monica, M.D., Ph.D.</investigator_affiliation>
    <investigator_full_name>Monica Montagnani</investigator_full_name>
    <investigator_title>Medical School Faculty Member - Professor of Pharmacology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
